Bayer Receives FDA Approval for Jivi ...

Bayer Receives FDA Approval for Jivi (antihemophilic factor...

Aug 31, 2018 Read more:

Bayer announced today that the U.S. Food and Drug Administration has approved JiviA for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older. The initial recommended prophylactic regimen for Jivi is twice weekly with the ability to dose every five days and further individually adjust to less or more frequent dosing based on bleeding episodes.

Start the conversation, or


Title Updated Last By Comments
News Baxter Initiates Phase I Clinical Trial of Long... (Jan '12) Jan '12 Karan Dhawan - Pu... 4
buy cheap Antihemophilic Factor (Nov '11) Nov '11 DrCarlos 1
recall koate-dvi (Oct '08) Oct '08 dr hashemi 1
News Recall of Antihemophilic Factor (Human), Koate-DVI (Oct '08) Oct '08 dr hashemi 1